Table 2. Patient characteristics (univariate VFA/SFA ratio analysis at the median).
| Variable | VFA/SFA <0.655 (%) | VFA/SFA ≥0.655 (%) | P value |
|---|---|---|---|
| T stage | 0.116 | ||
| Stage 1–2 | 17 (28.8) | 24 (42.9) | |
| Stage 3–4 | 42 (71.2) | 32 (57.1) | |
| N stage | 0.289 | ||
| N0 | 17 (28.8) | 21 (38.2) | |
| N1 | 42 (71.2) | 34 (61.8) | |
| Lymph nodes | 0.207 | ||
| ≥10 | 30 (47.6) | 23 (36.5) | |
| <10 | 33 (52.4) | 40 (63.5) | |
| Neoadjuvant therapy | 0.083 | ||
| No | 15 (23.8) | 24 (38.1) | |
| Yes | 48 (76.2) | 39 (61.9) | |
| Tumor size (cm) | 0.853 | ||
| 0–5 | 38 (61.3) | 39 (62.9) | |
| >5 | 24 (38.7) | 23 (37.1) | |
| Operation time (min) | 0.153 | ||
| ≤275 | 30 (47.6) | 38 (60.3) | |
| >275 | 33 (52.4) | 25 (39.7) | |
| Surgery | 0.087 | ||
| Transhiatal | 25 (39.7) | 16 (25.4) | |
| Transthoracic | 38 (60.3) | 47 (74.6) | |
| Histological grade | 0.471 | ||
| Well | 6 (11.3) | 9 (20.5) | |
| Moderate | 29 (54.7) | 20 (45.5) | |
| Poor | 18 (34.0) | 15 (34.0) | |
| Gender | 0.002 | ||
| Male | 48 (76.2) | 60 (95.2) | |
| Female | 15 (23.8) | 3 (4.8) | |
| Pathologic response to therapy | 0.289 | ||
| Complete | 14 (29.8) | 17 (46.0) | |
| Partial | 23 (48.9) | 15 (40.5) | |
| None | 10 (21.3) | 5 (13.5) | |
| Recurrence | 0.379 | ||
| No | 48 (76.2) | 52 (82.5) | |
| Yes | 15 (23.8) | 11 (17.5) | |
| Radial margins/residual tumor | 0.080 | ||
| R0 | 59 (95.2) | 62 (100.0) | |
| R1 | 3 (4.8) | 0 (0.0) |
VFA, visceral fat area; SFA, subcutaneous fat area.